Transcatheter Aortic Valve Implantation (TAVI) is a safe and effective treatment for patients with symptomatic aortic stenosis (AS). During a TAVI procedure a valve is implanted into the heart to help repair a damaged aortic valve. Aortic Stenosis is prevalent in older people, so as the population ages it’s estimated that by 2025 the number of TAVI procedures globally will reach 300,000. After undergoing a minimalist TAVI procedure, patients can be discharged the following day, called Next
Day Discharge (NDD) and has been effectively and successfully implemented in many TAVI centres globally, with benefits to the patient and healthcare system.
This project is the first Australian prospective study which will trial same day discharge (SDD) in suitable low-risk patients after TAVI. The project aims to demonstrate whether SDD is a feasible and safe clinical pathway. The researchers will establish a clinical pathway to identify patients eligible for SDD, and that they are comprehensively assessed for early signs of complications to ensure they can continue to recover safely at home.
If it proves successful it will provide a standardised framework for other centres, nationally and globally, to implement SDD practices. The goal being to improve patient outcomes and the accessibility of TAVI, while reducing the burden on a stretched hospital system.